- Research team uses Delphi process for the first time to identify ideal cannabis dosing guidelines.
- After several rounds of voting, the ‘global task force’ created three separate dosing protocols.
- RYAH Group’s suite of precision dosing devices provide a practical way to safely execute these — or any — recommended dosing guidelines.
Dosing recommendations are critical in any health treatments, but where cannabis is concerned, dosing levels have been tricky to identify. A recent blog from
RYAH Group (CSE: RYAH) notes that a team of more than 20 cannabis experts have published consensus recommendations for dosing and administration of medical cannabis to treat chronic pain (
https://ibn.fm/2BHJC). RYAH is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments.
“Despite hundreds of thousands of patients legally using medical cannabis to treat a broad spectrum of conditions, it remains frustratingly difficult to dose,” the Sept. 8 article states. “There are no official guidelines or dosing schedules. In large part, patients experiment independently, with information found online or based on vague suggestions from friends.
“Physicians, researchers, and lawmakers have struggled to craft policies around cannabis dosage guidelines,” the blog continued. “But, as medical cannabis earns more acceptance across the national and international health care community, there have been renewed attempts to settle on safe and standardized dosage recommendations.”
The article goes on to report that in a renewed attempt to identify clear, scientifically supported dosing recommendations, researchers applied the Delphi process to reach a dosage consensus regarding a specific condition; the team chose to focus on chronic pain. The researchers utilized the Delphi process, a systematic, interactive way of gaining opinions or agreement from a panel of independent experts, typically through surveys or questionnaires of some sort, to determine cannabis dosing (
https://ibn.fm/Ldklx). Results of the group’s efforts were published in the “Journal of Cannabis Research.”
The paper noted that “the modified Delphi process has been used extensively in health care settings to provide consensus-based recommendations on important clinical questions where randomized control trial data is lacking.” Cannabis dosing seemed perfectly suited to this approach.
“After several rounds of voting, the ‘global task force’ created three separate dosing protocols: routine administration, conservative administration, and rapid administration,” the RYAH blog noted. “Each is designed to ease a patient treating chronic pain into medical cannabis and treatment with THC if needed.
“Dosing guidelines like [these] just one-half of the equation,” the article continued. “The other half is the delivery mechanism. Patients need a reliable way to receive consistent and measurable doses, to adhere to their treatment protocol. Physicians also need a way to monitor patient titration and dose size.”
Enter RYAH Group.
RYAH Group’s suite of precision intake control and management devices provides a practical way to execute these — or any — volume control guidelines safely. The
RYAH Smart Patch,
Inhaler, and
Pen enable patients and physicians to control their medicine, the specific administration volume, and the protocol behind the treatment. In addition, detailed analytics provided by these RYAH devices help determine which intake volumes are working and what needs adjusting, and a patient’s progress in their treatment. It’s the data-driven approach to plant-based medicine desperately needed to help patients reach their goals faster.
“We want to create useful technology that collects, analyzes, and leverages objective data on therapeutic plant usage,” the company states. “A holistic approach to plant treatment is now possible thanks to RYAH products. Using smart devices, artificial intelligence, and an integrated platform, patients and doctors can stay on top of their prescriptions in a way that is both safe and seamless.”
For more information, visit the company’s website at
www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at
https://ibn.fm/RYAH
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.